Divided FTC conditionally clears Danaher/GE biopharma merger
Danaher must divest products in several markets to allay concerns that its $21 billion acquisition of GE’s biopharma business would harm competition, the Federal Trade Commission has held.
To read more
Subscribe to Global Competition Review
Subscribe and start reading now
Global Competition Review (GCR) is a leading global provider of competition law, regulation and enforcement information, combining data, deep market insight and a user-centric platform to provide our clients with powerful legal solutions.
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10